ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; CV = cardiovascular; EF = ejection fraction; HF = heart failure; HF(P/R)EF = HF (with preserved/reduced) EF; HR = hazard ratio; L/RV = left/right ventricular; RT = radiotherapy.
Exercise training effects on elderly and middle-age patients with chronic heart failure after acute decompensation Authors: Acanfora D et al. Summary: This randomised controlled trial enrolled patients with HF with LVEF <40% within 2 weeks of acute cardiogenic pulmonary oedema, including 40 elderly patients and 32 middle-aged patients, to participate in a 4-week supervised programme of closed-chain resistive activities and abdominal exercises. The exercise programme was associated with significant improvements in exercise duration, peak oxygen consumption and ventilatory threshold in both age groups (p<0.0001). Training significantly influenced previous cardiopulmonary parameters regardless of age, and catecholamine levels were significantly reduced.
Comment: While admission to hospital with acute decompensated HF is a crisis for patients suffering from chronic HF, it also provides an opportunity to review all aspects of the patient's management and initiate lifestyle interventions if these have not previously been considered. Ideally this should happen in the context of a multidisciplinary team. In this interesting single-centre randomised study, Italian investigators were able to demonstrate a significant benefit of exercise training in both middle-aged and elderly patients with ischaemic heart disease and HFREF 4 weeks after commencing a formal exercise training programme within 2 weeks of presenting to hospital with acute pulmonary oedema. A major limitation of the study was that patients on β-blockers were excluded.
Reference: Int J Cardiol 2016; 225:313-23 Abstract Improving medication titration in heart failure by embedding a structured medication titration plan Authors: Hickey A et al. Summary: This paper reported on a quality improvement project implemented in three Queensland HF disease management services. It involved the iterative implementation of a structured medication plan that employed methods such as awareness-raising/education, audit/feedback, integration into existing work practice and incentive payments. Compared with a pre-intervention cohort (n=96), two intervention cohorts (n=95 and 89) showed increased use of the titration plan, a shift to greater primary-care responsibility for titration, and more patients achieving target ACE inhibitor/ARB and β-blocker doses. When all three cohorts were combined, patients not on target doses on discharge who received a medication titration plan were significantly more likely to achieve target ACE inhibitor/ARB and β-blocker doses within 6 months.
Comment: This report from Queensland describes the results of a quality improvement programme aimed at increasing utilisation and uptitration of evidence-based therapies, namely ACE inhibitors/ARBs and β-blockers, in HFREF. A major aim of the programme was to improve communication and integration between hospital-based and community-based healthcare providers. An interesting feature of the programme was the use of an incentive payment for each completed uptitration. While the improvement in the proportion of patients achieving target doses of ACE inhibitors/ARBs and β-blockers following the intervention appears modest, the proportions of eligible patients receiving these drugs was more than 95%, which is a remarkable achievement in a real-world elderly chronic HF population.
Reference: Int J Cardiol 2016; 224:99-106 Abstract The healthcare costs of heart failure during the last five years of life Authors: Hollingworth W et al. Summary: The health system costs in England associated with HF during the last 5 years of life were estimated using retrospective, linked primary-care and mortality data from a cohort of 1555 adults. The per-patient cost of healthcare cost during the last 3 months of life was £8827, of which >90% was associated with inpatient or critical care. Time spent in hospital during the last 3 months of life averaged 17.8 days per patient, and there was an average of 8.8 primary-care consultations per patient. Most patients (59.9%) died in hospital. Compared with quarters prior to HF diagnosis, the healthcare costs during postdiagnosis quarters were greater by £1439. Costs were lower for older patients and those with lower comorbidity scores.
Comment:
The key finding of this UK registry study is that the healthcare costs of patients with HF escalate dramatically in the last 3 months of life, with 90% of these costs related to hospitalisation. More than 60% of HF patients die in hospital. While many interventions (including drugs, devices and multidisciplinary care) improve survival in HF, eventual progression of the HF syndrome means that the costs of care in the last few months of life, as identified in this study, will be postponed but not prevented by these interventions. The most effective way to reduce healthcare costs of terminally ill HF patients is to provide terminal care in the patient's home. Use of home-based palliative care services appears logical and has been shown to increase the probability of patients choosing to die at home; however, the cost effectiveness of these services remains inconclusive.
Reference: Int J Cardiol 2016; 224:132-8 Abstract Meta-analysis of association between mediastinal radiotherapy and long-term heart failure Authors: Nolan MT et al. Summary: Six studies (n=45,669) reporting data on the long-term risk of HF following thoracic RT for cancer were included in this meta-analysis; weighted median followup was 13.9 years. Pooled data showed a significantly increased risk of HF following thoracic RT (HR 1.83 [95% CI 1.09-3.08]), with significant heterogeneity among the studies (I 2 =88.47%), approximately 80% of which was explained by age at time of RT and follow-up duration. Significance of the association between thoracic RT and long-term HF was lost when studies of malignancies other than breast cancer or haematological malignancies and those with Newcastle-Ottawa scores <8 were excluded, but the magnitude of the risk remained about the same. An association was seen between earlier publication date and increased HF risk with RT. The study conclusions were not significantly impacted by other variables.
In another publication relevant to cardio-oncology, Australian authors conducted a meta-analysis of studies (mainly from the Netherlands) examining the risk of adult patients developing symptomatic HF more than 5 years following mediastinal RT for malignancy. They found that the risk of long-term HF is approximately doubled following RT. The risk appeared to be higher in those of younger median age at the time of RT and with longer duration of follow-up. These findings support current guidelines, which recommend echocardiographic screening 5-10 years after completion of RT with repeat echocardiography every 5 years thereafter. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction Authors: Kaye DM et al.
Summary:
The long-term benefits of a novel interatrial septal shunt device for reducing left atrial pressure in HFPEF were investigated in 64 patients with LVEF ≥40%, NYHA (New York Heart Association) class II-IV and pulmonary capillary wedge pressure ≥15mm Hg at rest or ≥25mm Hg during supine bicycle exercise. Sustained, significant improvements were seen in NYHA class, quality of life and 6-minute walk distance 1 year after device implantation. Echocardiography revealed a small but stable and significant reduction in LV end-diastolic volume index, along with a small but stable and significant increase in the RV end-diastolic volume index. Invasive haemodynamic data from a subset of patients revealed a sustained, significant reduction in workload-corrected exercise pulmonary capillary wedge pressure. The 1-year survival rate was 95%, with no evidence of device-related complications.
Comment: Creation of an interatrial shunt using an investigational interatrial septal device has been shown to relieve symptoms of pulmonary congestion and improve exercise capacity and haemodynamics in patients with HFPEF. The initial publication in the Lancet of this international multicentre trial (including several centres in Australia and New Zealand) reported these outcomes after 6 months follow-up (see commentary in Issue 35 of Heart Failure Research Review). The current paper examined the 12-month outcomes and confirmed that the benefits observed at 6 months were sustained at 12 months with no device-related complications. Further follow-up and larger trials are needed, but results to date suggest that the interatrial septal device is a promising treatment option for patients with HFPEF. In a similar study conducted by Italian investigators, the authors reported higher rates of worsening renal function and more adverse events during 6 months follow-up in patients receiving continuous infusions or higher doses of furosemide. In this post hoc analysis of the trial, they report that reduced diuretic efficiency (or diuretic resistance) was associated with worse outcomes. This could be explained by more advanced HF or renal disease in the group with reduced diuretic efficiency. It is noteworthy that the average age of patients in the Italian study was 80 years compared with 66 years in the DOSE study.
Reference: Int J Cardiol 2016; 224:213-9 Abstract Fluid status telemedicine alerts for heart failure Authors: Böhm M et al., on behalf of the OptiLink HF Study Investigators Summary: Patients with a recently implanted cardioverter defibrillator with or without cardiac resynchronisation therapy (n=1002) were randomised to automatic transmission of audible text-message fluid status alerts to the responsible physician or to standard care. A protocol-specified algorithm with remote review of device data and telephone contact was prescribed to assess symptoms and initiate treatment after the alert was transmitted in the intervention arm. The alert transmission failure rate was 24%, and 30% of alerts were followed by medical interventions. There was no significant difference between the intervention and standard care arms for all-cause death or CV-related hospitalisation (composite primary endpoint; 45.0% vs. 48.1%; HR 0.87 [95% CI 0.72-1.04]) or mortality rate (11.7% vs. 12.7%; 0.89 [0.62-1.28]) over average follow-up of 1.9 years.
Comment: The implantation of pacemakers or similar devices capable of determining the fluid status of an individual at risk of worsening HF and then automatically transmitting warnings of fluid overload to the caring physician has intuitive appeal. This large industry-sponsored randomised trial was designed to test the effectiveness of this concept. The results were disappointing, demonstrating that despite physicians receiving automated text messages regarding fluid overload in the intervention group, the overall outcome of the intervention group was no better than usual care. This may be explained in part by the relatively low rate of intervention (30%) following telemedicine alerts, despite intensive physician and patient education prior to trial enrolment.
Reference: Eur Heart J 2016; 37(41) :3154-63 Abstract
